Van To Tsai

Title: Van To Tsai: Innovator in Vaccine-Based Immunotherapy

Introduction

Van To Tsai is a prominent inventor based in San Diego, CA. He has made significant contributions to the field of immunotherapy, particularly in the development of vaccine-based treatments for prostate-associated antigens. With a total of four patents to his name, Tsai is recognized for his innovative approaches to cancer treatment.

Latest Patents

Tsai's latest patents focus on prostate-associated antigens and vaccine-based immunotherapy regimens. The disclosures include isolated immunogenic PAA polypeptides, isolated nucleic acid molecules encoding these polypeptides, and vaccine compositions that incorporate them. Additionally, the patents outline methods for utilizing these polypeptides and nucleic acids, as well as vaccine-based immunotherapy regimens that involve the co-administration of a vaccine alongside an immune-suppressive-cell inhibitor and an immune-effector-cell enhancer.

Career Highlights

Tsai is currently employed at Pfizer Corporation, where he continues to advance his research in immunotherapy. His work has the potential to significantly impact the treatment of prostate cancer and improve patient outcomes.

Collaborations

Some of Tsai's notable coworkers include Helen Kim Cho and Brian Gregory Pierce. Their collaborative efforts contribute to the innovative research environment at Pfizer Corporation.

Conclusion

Van To Tsai is a key figure in the field of vaccine-based immunotherapy, with a focus on prostate-associated antigens. His patents and ongoing research at Pfizer Corporation highlight his commitment to advancing cancer treatment.